0001209191-18-047108.txt : 20180816
0001209191-18-047108.hdr.sgml : 20180816
20180816171243
ACCESSION NUMBER: 0001209191-18-047108
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180814
FILED AS OF DATE: 20180816
DATE AS OF CHANGE: 20180816
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Williams Kristen Marie
CENTRAL INDEX KEY: 0001296965
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 181023977
MAIL ADDRESS:
STREET 1: C/O PACIRA PHARMACEUTICALS, INC.
STREET 2: 5 SYLVAN WAY, SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER NAME:
FORMER CONFORMED NAME: Dunker Kristen Marie
DATE OF NAME CHANGE: 20040712
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 510619477
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-254-3560
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-08-14
0
0001396814
Pacira Pharmaceuticals, Inc.
PCRX
0001296965
Williams Kristen Marie
C/O PACIRA PHARMACEUTICALS, INC.
5 SYLVAN WAY, SUITE 300
PARSIPPANY
NJ
07054
0
1
0
0
CAO and General Counsel
Common Stock
2018-08-14
4
S
0
4773
47.04
D
22374
D
The sales reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.80 to $47.243, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ Kristen Williams
2018-08-16